946-P: Insulin Pump Therapy in Type 1 Diabetes—a Real-World Study of Mortality and Clinical Outcomes

Introduction 0.001). Conclusion: In a large real-world cohort of people with T1D, insulin pumps compared to MDI were associated with lower overall mortality. Clinically significant reductions in HbA1c were seen in both groups. The risk of DKA, stroke and ischemic heart disease was higher in the first year of pump use but with no difference compared to MDI at year 5. Increased diabetes related eye disease in the pump group may represent a legacy effect of prior sub-optimal control. Disclosure S. Haughton: None. D. Riley: None. M. Arshad: None. S. Azmi: None. R.A. Malik: Speaker's Bureau; Lilly Diabetes, Sanofi, Novo Nordisk, Viatris Inc. U. Alam: Other Relationship; Procter Sanofi-Aventis Deutschland GmbH, Eli Lilly and Company, Grunenthal. A. Iqbal: Advisory Panel; Abbott. Speaker's Bureau; AstraZeneca, Dexcom, Inc.